Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.

Peroxisome-proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that regulates cell proliferation, differentiation, and apoptosis. In vivo studies were performed to evaluate the activities of two thiazolidinedione PPARγ agonists, rosiglitazone and pioglitazone, as inh...

Full description

Saved in:
Bibliographic Details
Main Authors: David L McCormick, Thomas L Horn, William D Johnson, Xinjian Peng, Ronald A Lubet, Vernon E Steele
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141849&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850125017947308032
author David L McCormick
Thomas L Horn
William D Johnson
Xinjian Peng
Ronald A Lubet
Vernon E Steele
author_facet David L McCormick
Thomas L Horn
William D Johnson
Xinjian Peng
Ronald A Lubet
Vernon E Steele
author_sort David L McCormick
collection DOAJ
description Peroxisome-proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that regulates cell proliferation, differentiation, and apoptosis. In vivo studies were performed to evaluate the activities of two thiazolidinedione PPARγ agonists, rosiglitazone and pioglitazone, as inhibitors of oral carcinogenesis in rats. Oral squamous cell carcinomas (OSCC) were induced in male F344 rats by 4-nitroquinoline-1-oxide (NQO; 20 ppm in the drinking water for 10 weeks). In each study, groups of 30 NQO-treated rats were exposed to a PPARγ agonist beginning at week 10 (one day after completion of NQO administration) or at week 17 (7 weeks post-NQO); chemopreventive agent exposure was continued until study termination at week 22 (rosiglitazone study) or week 24 (pioglitazone study). Administration of rosiglitazone (800 mg/kg diet) beginning at week 10 increased survival, reduced oral cancer incidence, and reduced oral cancer invasion score in comparison to dietary controls; however, chemopreventive activity was largely lost when rosiglitazone administration was delayed until week 17. Administration of pioglitazone (500 mg/kg diet beginning at week 10 or 1000 mg/kg diet beginning at week 17) induced significant reductions in oral cancer incidence without significant effects on OSCC invasion scores. Transcript levels of PPARγ and its three transcriptional variants (PPARγv1, PPARγv2, and PPARγv3) were not significantly different in OSCC versus age- and site-matched phenotypically normal oral tissues from rats treated with NQO. These data suggest that PPARγ provides a useful molecular target for oral cancer chemoprevention, and that overexpression of PPARγ at the transcriptional level in neoplastic lesions is not essential for chemopreventive efficacy.
format Article
id doaj-art-56ce08f91b1a421f9bdca714484e37aa
institution OA Journals
issn 1932-6203
language English
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-56ce08f91b1a421f9bdca714484e37aa2025-08-20T02:34:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011010e014184910.1371/journal.pone.0141849Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.David L McCormickThomas L HornWilliam D JohnsonXinjian PengRonald A LubetVernon E SteelePeroxisome-proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that regulates cell proliferation, differentiation, and apoptosis. In vivo studies were performed to evaluate the activities of two thiazolidinedione PPARγ agonists, rosiglitazone and pioglitazone, as inhibitors of oral carcinogenesis in rats. Oral squamous cell carcinomas (OSCC) were induced in male F344 rats by 4-nitroquinoline-1-oxide (NQO; 20 ppm in the drinking water for 10 weeks). In each study, groups of 30 NQO-treated rats were exposed to a PPARγ agonist beginning at week 10 (one day after completion of NQO administration) or at week 17 (7 weeks post-NQO); chemopreventive agent exposure was continued until study termination at week 22 (rosiglitazone study) or week 24 (pioglitazone study). Administration of rosiglitazone (800 mg/kg diet) beginning at week 10 increased survival, reduced oral cancer incidence, and reduced oral cancer invasion score in comparison to dietary controls; however, chemopreventive activity was largely lost when rosiglitazone administration was delayed until week 17. Administration of pioglitazone (500 mg/kg diet beginning at week 10 or 1000 mg/kg diet beginning at week 17) induced significant reductions in oral cancer incidence without significant effects on OSCC invasion scores. Transcript levels of PPARγ and its three transcriptional variants (PPARγv1, PPARγv2, and PPARγv3) were not significantly different in OSCC versus age- and site-matched phenotypically normal oral tissues from rats treated with NQO. These data suggest that PPARγ provides a useful molecular target for oral cancer chemoprevention, and that overexpression of PPARγ at the transcriptional level in neoplastic lesions is not essential for chemopreventive efficacy.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141849&type=printable
spellingShingle David L McCormick
Thomas L Horn
William D Johnson
Xinjian Peng
Ronald A Lubet
Vernon E Steele
Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
PLoS ONE
title Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
title_full Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
title_fullStr Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
title_full_unstemmed Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
title_short Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
title_sort suppression of rat oral carcinogenesis by agonists of peroxisome proliferator activated receptor γ
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0141849&type=printable
work_keys_str_mv AT davidlmccormick suppressionofratoralcarcinogenesisbyagonistsofperoxisomeproliferatoractivatedreceptorg
AT thomaslhorn suppressionofratoralcarcinogenesisbyagonistsofperoxisomeproliferatoractivatedreceptorg
AT williamdjohnson suppressionofratoralcarcinogenesisbyagonistsofperoxisomeproliferatoractivatedreceptorg
AT xinjianpeng suppressionofratoralcarcinogenesisbyagonistsofperoxisomeproliferatoractivatedreceptorg
AT ronaldalubet suppressionofratoralcarcinogenesisbyagonistsofperoxisomeproliferatoractivatedreceptorg
AT vernonesteele suppressionofratoralcarcinogenesisbyagonistsofperoxisomeproliferatoractivatedreceptorg